Zaid Admani

In fact, it was Goldman's highest profit in about five years.

But there was a problem.

Their fixed income trading business really disappointed.

Revenues actually dropped 10% to $4 billion.

The bank blamed this on lower revenues coming from their interest rate products and mortgages.

And because of that miss, Goldman stock is down around 4% this morning, despite the overall earnings beat.

Wall Street seems to be zeroing in on the fixed income division and wondering what it means for the rest of the year, especially with the Iran situation still unresolved.

We'll get a better picture of the banking sector later this week when we hear from JP Morgan, Citi, Wells Fargo, Bank of America.

So stay tuned for that.

Let's talk about some stocks making moves today.

Shares of Revolution Medicines are absolutely skyrocketing today after the biotech company announced a major breakthrough in pancreatic cancer treatment.

The company says that one of its drugs, which I'm not going to try to pronounce,

succeeded in a late stage phase three trial and almost doubled patient survival compared to chemotherapy.

Patients taking the pill lived a median of 13.2 months versus 6.7 for patients on chemotherapy.

And the drug also cut the risk of death by 60%.

Now, pancreatic cancer has some of the lowest five-year survival rates of any major cancer at just 13%.

And until now, the only treatment option for these patients was chemotherapy.

So this will be a game changer.

Revolution Medicine says it plans to move quickly and seek FDA approval.

That caught the attention of Wall Street and shares of the company are up more than 35% at the time of this recording.